02137.HK
Brii Biosciences Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.93
+2.20%Year over year
Reported trailing growth
- Revenue
- -70.3%
- EBITDA
- +33.1%
- EBIT
- +32.6%
- EPS
- +7.3%
- Free cash flow
- +66.1%
- Operating cash flow
- +56.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -29.5%
- EBITDA
- +26.0%
- EBIT
- +25.9%
- Net income
- +57.3%
- EPS
- +57.1%
- Free cash flow
- +23.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026